Analysed ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) News Sources
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
30-09-2026
yahoo.com
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01-10-2026
yahoo.com
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
01-10-2026
yahoo.com
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
05-10-2026
yahoo.com
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
07-10-2026
yahoo.com
Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes
09-10-2026
yahoo.com
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
09-10-2026
biopharmadive.com
Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success
10-10-2026
yahoo.com
What is the current price of ZEALAND PHARMA A/S (ZLDPF:OTCMKTS)?
The current price of ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) is $35.645.
ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) since the previous trading day is $-1.895.
ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) since the previous trading day is -5.0479%.
What is the most recent average sentiment score for ZEALAND PHARMA A/S (ZLDPF:OTCMKTS)?
The most recent average sentiment score for ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) is 43 out of 100.
What is the most recent average sentiment for ZEALAND PHARMA A/S (ZLDPF:OTCMKTS)?
The most recent sentiment for ZEALAND PHARMA A/S (ZLDPF:OTCMKTS) is .
SEC-8K** Filing Available For ZEALAND PHARMA A/S (ZLDPF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.